Compare Intel Corp (INTC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Twist Bioscience Corp — how do they compare? Intel Corp trades at $104.7 (market cap $566.04B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Intel Corp is far larger — about 56.2× Twist Bioscience Corp's market cap, and Intel Corp pays a 2.24% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Twist Bioscience Corp for 27 Days on average.
| INTC | TWST | |
|---|---|---|
Market Cap | $566.04B | $10.08B |
Volume | 118,475,837 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $140.94 | $205.00 |
52-Week Low | $33.62 | $25.45 |
Typical Hold Time | 116 Days | 27 Days |
Enterprise Value | $586.85B | $10.01B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $107.08, down 5.34% today, but maintains a bullish technical outlook with strong support at $104. The stock has surged over 220% year-to-date amid AI-driven momentum. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.42 exceeding estimates. However, the company posted a net loss of -$267 million in 2025, reflecting margin pressures. Cash flow improved with $6.46 billion net inflow in 2025, though debt levels remain elevated.
Intel's turnaround story hinges on its foundry expansion and AI chip demand, but high valuation ratios and negative profitability metrics pose risks. Analyst consensus is cautious with a $111.72 price target and 54% hold ratings. Competitive threats from TSMC and AMD require careful monitoring for sustained growth.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
